These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7977011)

  • 1. Lipid-lowering trials: results and limitations.
    Furberg CD
    Am Heart J; 1994 Dec; 128(6 Pt 2):1304-8. PubMed ID: 7977011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol lowering and mortality: the importance of considering initial level of risk.
    Smith GD; Song F; Sheldon TA
    BMJ; 1993 May; 306(6889):1367-73. PubMed ID: 8518602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention?
    Green L
    Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future of lipid-lowering trials: what else do we need to know?
    Jones PH
    Am J Cardiol; 1998 Sep; 82(6A):32M-38M. PubMed ID: 9766346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering therapy after coronary artery bypass grafting: time for more aggressive intervention.
    Lucas BD
    Am J Health Syst Pharm; 2002 Nov; 59(21):2101-3. PubMed ID: 12434726
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials.
    Pignone M; Phillips C; Mulrow C
    BMJ; 2000 Oct; 321(7267):983-6. PubMed ID: 11039962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins.
    Pearson TA
    Am J Cardiol; 1998 Nov; 82(10A):28S-30S. PubMed ID: 9860353
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary prevention of cardiovascular disease: implications of lipid-lowering trials.
    Pedersen TR
    J Hypertens Suppl; 1996 Dec; 14(5):S195-200. PubMed ID: 9120679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now.
    Fonarow GC; Ballantyne CM
    Circulation; 2001 Jun; 103(23):2768-70. PubMed ID: 11401927
    [No Abstract]   [Full Text] [Related]  

  • 12. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis.
    Labreuche J; Deplanque D; Touboul PJ; Bruckert E; Amarenco P
    Atherosclerosis; 2010 Sep; 212(1):9-15. PubMed ID: 20457452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of lipid-lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System.
    Rubins HB; Nelson DB; Noorbaloochi S; Nugent S
    Am J Cardiol; 2003 Nov; 92(10):1177-82. PubMed ID: 14609592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of coronary angiography on use of lipid-lowering agents in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. For the WISE Investigators.
    Bittner V; Olson M; Kelsey SF; Rogers WJ; Bairey Merz CN; Armstrong K; Reis SE; Boyette A; Sopko G
    Am J Cardiol; 2000 May; 85(9):1083-8. PubMed ID: 10781756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes.
    Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA;
    BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912
    [No Abstract]   [Full Text] [Related]  

  • 17. Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels.
    Havel RJ
    Circulation; 1997 Oct; 96(7):2113-4. PubMed ID: 9337175
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.
    Upadhyay A; Earley A; Lamont JL; Haynes S; Wanner C; Balk EM
    Ann Intern Med; 2012 Aug; 157(4):251-62. PubMed ID: 22910936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention of coronary disease with lipid-lowering drugs.
    Lancet; 1989 Mar; 1(8636):473-4. PubMed ID: 2563844
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.